Novel somatostatin derivatives

Details Novel somatostatin derivatives Novel somatostatin derivatives

1987-02-25

1989-06-06

Phillips, Delbert R.

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

Somatostatin ; related peptides

514 10, 530317, 530338, C07K 726, C07K 764, A61K 3702

Patent

active

048373036

DESCRIPTION:

BRIEF SUMMARY
BACKGROUND OF THE INVENTION

The invention relates to somatostatin derivatives of general Formula I ##STR3## wherein at least one of the residues X represents a moiety, bound to the free amino group of alanine or lysine, of Formula II ##STR4## with R meaning an alkyl group containing 7-23 carbon atoms, and the residues X which may remain mean hydrogen atoms.
The invention furthermore concerns a process for the production of these somatostatin derivatives and pharmaceutical preparations containing these compounds.
As is known, somatostatin is a pharmacologically active compound utilized, inter alia, for the treatment of diabetes mellitus and gastrointestinal disorders S. M. McCann, Ann. Rev. Pharmacol. Toxicol. 1982, 22: 491-515; K. Gerbitz, Nachr. Chem. Techn. 1975, 23: 355-357; K. Gyr, Trends in Pharmacol. Sci., 1983, 3: 367-369; and S. Reichlin, N. Engl. Med. 1983, 309: 1495-1501 and 1556-1563.
Disadvantages of this compound are, inter alia, its inadequately specific activity and its rapid drop in efficacy.


SUMMARY OF THE INVENTION

The somatostatin derivatives of this invention according to general Formula I exhibit the same direction of activity as somatostatin proper, but are distinguished over this compound by a more specific effectiveness and a longer duration of activity.
The somatostatin derivatives of this invention can be produced from somatostatin and the acids of general Formula III under conditions conventionally employed in peptide synthesis for the establishment of acid amide linkages (Houben-Weyl, Methoden der organischen Chemie, Georg Thieme Publishers, Stuttgart, Fed. Republic of Germany, 4th ed, vol. XV/1, Synthesis of Peptides, part 1, 1974, pp. 28 et seq.). Thus somatostatin can be N-acylated with an acid of Formula III ##STR5## wherein R is as defined above, or with a reactive derivative thereof.
Thus, it is possible, for example, to react the carboxylic acids under the conventional conditions with somatostatin in the presence of dicyclohexylcarbodiimide, or the acids are converted into the corresponding acid chlorides or mixed anhydrides, and these are reacted with somatostatin in a manner known per se.
The acids of general Formula III utilized as the starting compounds can contain, as substituent R, alkyl groups of 7-23 carbon atoms and having equal or differing chain lengths. These alkyl groups are preferably straight-chain and exhibit an odd number of carbon atoms. Examples of alkyl groups are: the heptyl group, the nonyl group, the undecyl group, the tridecyl group, the pentadecyl group, the heptadecyl group, the nonadecyl group, the heneicosyl group and the tricosyl group.
Suitable starting compounds for the process of this invention are the following acids, for example, N-palmitoyl-S-(2[R,S],3-dilanroyloxypropyl-L-cysteine, N-palmitoyl-S-(2[R,S],3-dipalmitoyloxypropyl)-L-cysteine, N-octanoyl-S-(2[R,S],3-didecanoyloxypropyl)-L-cysteine, N-octanoyl-S-(2[R,S],3-didodecanoyloxypropyl)-L-cysteine, N-octanoyl-S-(2[R,S],3-dioctanoyloxypropyl)-L-cysteine, N-eicosanoyl-S-(2[R,S],3-dioctanoyloxypropyl)-L-cysteine, N-tetracosanoyl-S-(2[R,S],3-dioctanoyloxypropyl)-L-cysteine, and N-stearoyl-S-(2[R,S],3-distearoyloxypropyl)-L-cysteine.
The acids of general Formula III can be produced by acylation of compounds of Formula IV ##STR6## which, in turn, can be synthesized in accordance with the process described in European Patent Application No. 114787.
The compounds according to the invention can be processed into pharmaceutical preparations by adding the customary auxiliary agents and/or excipients. Thus, it is possible, for example, to convert the more hydrophilic somatostatin derivatives of general Formula I optionally with the addition of solubilizers (approximately up to 1% by weight of "Cremophor" or up to 30% by weight of propylene glycol), buffers (phosphate buffer, tris buffer), sodium chloride, etc., into aqueous injection solutions or infusion solutions. On the other hand, it is also possible to process these compounds with addition of the conventional excipients (lactose, galacto

REFERENCES:
patent: 3998795 (1976-12-01), Sarantakis
patent: 4061608 (1977-12-01), Sarantakis
patent: 4118380 (1978-10-01), Immer et al.
patent: 4180500 (1979-12-01), Sarantakis et al.
patent: 4190575 (1980-02-01), Sarantakis
patent: 4358439 (1982-11-01), Sieber et al.
patent: 4439425 (1984-03-01), Tarcsay et al.
Chem. Abs., vol. 101, 1984, 211690s.
Somatostatin, Vale et al., pp. 365-397, (1972).
Samatostatin, Insulin & Glucagon, Brown et al., pp. 336-343.

Affiliated with

Also associated with

Rating

Novel somatostatin derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Novel somatostatin derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Novel somatostatin derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-41152